Catheter Precision (VTAK) announces that it has closed the previously announced acquisition of PeriKard. David Jenkins, CEO of Catheter Precision, commented on the acquisition, “We are happy to have closed on this all-stock transaction within our anticipated timeline. The acquired technology will complement our emphasis on the ventricular therapeutic market and expectation for continuing growth in this market segment”.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTAK: